AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to ...
The AlphaMeld platform empowers key functional stakeholders, including those involved in early drug discovery, target identification, competitive intelligence, and clinical trial optimization. By ...
Yahoo Finance4 天
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to ...
Ltd. (Kyowa Kirin), a Japan-based global specialty pharmaceutical company. The enhanced partnership provides enterprise-wide access to AlphaMeld Corporation’s proprietary AI-powered AlphaMeld ...
MarketWatch5 天
Kyowa Kirin Co. Ltd.
Copyright © 2025 MarketWatch, Inc. All rights reserved.
Pharmaceutical Technology10 天
Rocatinlimab by Kyowa Kirin for Asthma: Likelihood of Approval
Rocatinlimab is under clinical development by Kyowa Kirin and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) ...
MarketWatch16 天
Kyowa Hakko Kirin Co. Ltd. ADR
Copyright © 2025 MarketWatch, Inc. All rights reserved.
akm5 天
Japan's Kyowa Kirin sells Chinese division for $100 million
The Japanese pharmaceutical company Kyowa Kirin Co. plans to sell shares in the Chinese division of the Hong Kong company WinHealth Pharma Group Co. for 15 billion yen ($100 million) as part of the ...
Pharmaceutical Technology13 天
Rocatinlimab by Kyowa Kirin for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
Rocatinlimab is under clinical development by Kyowa Kirin and currently in Phase III for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase III drugs for Atopic Dermatitis (Atopic ...
pharmaphorum7 天
Grünenthal buys into Kyowa Kirin's mature medicines portfolio
German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan's Kyowa Kirin, which are currently sold by affiliate companies across Europe. The ...